Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases

Neurology. 2001 Jan 9;56(1):94-6. doi: 10.1212/wnl.56.1.94.

Abstract

The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Male
  • Middle Aged
  • Myasthenia Gravis / drug therapy*
  • Mycophenolic Acid / administration & dosage*
  • Mycophenolic Acid / adverse effects
  • Mycophenolic Acid / analogs & derivatives
  • Myositis / drug therapy
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Mycophenolic Acid